Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

CG Oncology Inc. (CGON)

NASDAQ: CGON · Biological Products, (No Diagnostic Substances) · Dallas, TX

Our rating: Cautious

Cautious reaffirmed at $74.74, moderate conviction, November 9, 2026.

Breaks if: The cautious call is wrong if CG Oncology's filings show product revenue exceeding $75 million on an annualized run rate within the next two quarterly reports, demonstrating that a commercial launch is gaining traction quickly enough to begin justifying the $6.7 billion market cap. On the upside, a sustained move above $100 within six months — anchored to disclosed revenue progress rather than momentum — would signal the market has credible evidence the thesis is playing out ahead of this timeline. Conversely, the call is reinforced rather than invalidated if free cash flow deteriorates beyond negative $170 million annualized without a corresponding revenue line appearing in the filings.

Key figures

Market value$7.1B
Revenue, last 12 months$6M
Net income, last 12 months−$237M
Free cash flow, last 12 months−$189M
Price to earningsn/a
Free cash flow yield−2.7%
Dividend yield0.0%
Operating margin−4293.5%
Return on equity−28.3%
Beta to the S&P 5001.31
Volatility, annualized60.9%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$2M−3.7%$-0.64−$49M
June 30, 2026$1Mn/a$-0.90−$47M
March 31, 2026$1M1982.7%$-0.71−$57M
December 31, 2025$2M409.2%$-0.51−$36M
September 30, 2025$2M3774.4%$-0.57−$39M
June 30, 2025$0.00−100.0%$-0.54−$28M
March 31, 2025$52000.00−90.2%$-0.45−$29M
December 31, 2024$456000.0045500.0%$-0.48−$21M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

20 ledger entries and 7 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.